Tadalafil for

Sexual Health

Tadalafil for

Sexual Health

$65 / Month

On Demand –  15 Tabs / 5 refills

$75 / Month

Daily – 30 Tabs / 5 refills

$175 / 3-Months

On Demand – 45 Tabs / 3-Months

$200 / 3-Months

Daily – 90 Tabs / 3-Months

What is Tadalafil?

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor approved for erectile dysfunction (ED) and available for both daily and on-demand use. Daily dosing (2.5–5 mg once daily) provides continuous plasma levels, allowing for spontaneous sexual activity, while on-demand dosing (10–20 mg prior to sexual activity) is taken as needed, typically 30 minutes before intercourse, with effects lasting up to 36 hours.

Are NuSex Medications Right for You?

NuSex medications are a great option for anyone looking to boost their vascular function and improve their overall health. You may benefit from NuSex medications if you want to enhance sexual or workout performance, boost your daily stamina, and improve mental focus.
Before starting any new medication, it’s always best to consult a medical provider to determine if NuSex medications are right for you and your health goals.

Frequently Asked Questions

Daily dosing allows for spontaneous sexual activity; on-demand is taken before intercourse

Headache, dyspepsia, back pain, myalgia, nasal congestion, flushing.

Patients on nitrates, those with unstable cardiovascular disease, recent MI, or stroke.

Caution is advised; may potentiate hypotensive effects.

Tadalafil: 17.5 hours; Sildenafil: 4 hours.

Seek emergency medical attention (risk of priapism).

Concomitant nitrate use (risk of severe hypotension); caution with alpha-blockers and significant cardiac disease.

References

Wright P. J. (2006). Comparison of phosphodiesterase type 5 (PDE5) inhibitors. International journal of clinical practice, 60(8), 967–975. https://doi.org/10.1111/j.1742-1241.2006.01049.x

Virani, S, Newby, L, Arnold, S. et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. JACC. 2023 Aug, 82 (9) 833–955. https://doi.org/10.1016/j.jacc.2023.04.003

 Coward, R. M., & Carson, C. C. (2008). Tadalafil in the treatment of erectile dysfunction. Therapeutics and clinical risk management, 4(6), 1315–1330. https://doi.org/10.2147/tcrm.s3336

Porst, H., Hell-Momeni, K., & Büttner, H. (2012). Chronic PDE-5 inhibition in patients with erectile dysfunction – a treatment approach using tadalafil once-daily. Expert opinion on pharmacotherapy, 13(10), 1481–1494. https://doi.org/10.1517/14656566.2012.693162

 Wei JT, Dauw CA, Brodsky CN. Lower Urinary Tract Symptoms in Men: A Review. JAMA. 2025;334(9):809–821. https://jamanetwork.com/journals/jama/article-abstract/2836455

Buvat, J., Büttner, H., Hatzimouratidis, K., Vendeira, P. A., Moncada, I., Boehmer, M., Henneges, C., & Boess, F. G. (2013). Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. The journal of sexual medicine, 10(6), 1592–1602. https://doi.org/10.1111/jsm.12130

Experience The Future Of Metabolic Optimization With Nucore.